Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.56 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2134237 | 0.87 | HDAC1 (0.69) | CYP2C9CACNA1BAPBA1RXFP1KMT2A | |
| SCHEMBL14810361 | 0.81 | CYP1A2 (0.60) | CYP2C9KMT2AHDAC1HDAC8HDAC6 | |
| SCHEMBL2132831 | 0.80 | RXFP1 (0.48) | CYP2C9CACNA1BAPBA1RXFP1KMT2A | |
| SCHEMBL10961901 | 0.80 | PTPN1 (0.70) | CYP2C9CACNA1BAPBA1RXFP1KMT2A | |
| SCHEMBL13181139 | 0.79 | HDAC1 (0.59) | CYP2C9RXFP1KMT2AMEN1HDAC1 | |
| SCHEMBL14701415 | 0.79 | HPGD (0.70) | CACNA1BAPBA1KMT2AMEN1HDAC1 | |
| SCHEMBL19462541 | 0.77 | HDAC1 (0.73) | CACNA1BAPBA1RXFP1KMT2AMEN1 | |
| SCHEMBL19462596 | 0.77 | HDAC1 (0.73) | CACNA1BAPBA1KMT2AMEN1HDAC1 | |
| SCHEMBL2606722 | 0.77 | HDAC1 (0.59) | CACNA1BAPBA1KMT2AMEN1HDAC1 | |
| SCHEMBL17599502 | 0.77 | CYP1A2 (0.58) | CYP2C9HDAC1HDAC8HDAC6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101147-A1 | INHIBITION OF HDAC2 TO PROMOTE MEMORY | HDAC2, HDAC1, HDAC3 | CYP2C9 4875/4885CACNA1B 1148/4885APBA1 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.